Trial on LRRK2 mutation in Parkinson’s disease is about to be completed.
Our Clinical Trials Unit is the lead international recruiter for this Phase 1 trial.
A hope for patients with Parkinson’s disease and this mutation. Keep informed!
Related Stories
16 de enero de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
3 de junio de 2021
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
3 de junio de 2021
This study could improve the efficacy and safety of the products being evaluated to try…
22 de julio de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
12 de diciembre de 2019
Grifols has reported to the press the positive result of the AMBAR trial in patients…
5 de noviembre de 2019
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
19 de julio de 2019
We have been selected to evaluate an innovative therapy in this terrible disease. We will…
20 de marzo de 2019
The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa,…